Kao SC - Search Results

1

Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma.

Kirschner MB, Cheng YY, Badrian B, Kao SC, Creaney J, Edelman JJ, Armstrong NJ, Vallely MP, Musk AW, Robinson BW, McCaughan BC, Klebe S, Mutsaers SE, van Zandwijk N, Reid G. Kirschner MB, et al. Among authors: kao sc. J Thorac Oncol. 2012 Jul;7(7):1184-91. doi: 10.1097/JTO.0b013e3182572e83. J Thorac Oncol. 2012. PMID: 22617246 Free article.

2

Pleural well-differentiated papillary mesothelioma: a case report.

Kao S, Mahon K, Lin B, Rutland J, Pawsey C, McCaughan B, Beale P. Kao S, et al. J Thorac Oncol. 2009 Jul;4(7):920-2. doi: 10.1097/JTO.0b013e3181a97dc3. J Thorac Oncol. 2009. PMID: 19550246 Free article.

3

Malignant mesothelioma.

Kao SC, Reid G, Lee K, Vardy J, Clarke S, van Zandwijk N. Kao SC, et al. Intern Med J. 2010 Nov;40(11):742-50. doi: 10.1111/j.1445-5994.2010.02223.x. Intern Med J. 2010. PMID: 20298508 Review.

4

High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.

Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, Clarke SJ. Kao SC, et al. Clin Cancer Res. 2010 Dec 1;16(23):5805-13. doi: 10.1158/1078-0432.CCR-10-2245. Epub 2010 Oct 18. Clin Cancer Res. 2010. PMID: 20956618

5

Validation of tissue microarray technology in malignant pleural mesothelioma.

Kao SC, Lee K, Armstrong NJ, Clarke S, Vardy J, van Zandwijk N, Reid G, Burn J, McCaughan BC, Henderson DW, Klebe S. Kao SC, et al. Pathology. 2011 Feb;43(2):128-32. doi: 10.1097/PAT.0b013e328342016c. Pathology. 2011. PMID: 21233673

6

Haemolysis during sample preparation alters microRNA content of plasma.

Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk N, Reid G. Kirschner MB, et al. Among authors: kao sc. PLoS One. 2011;6(9):e24145. doi: 10.1371/journal.pone.0024145. Epub 2011 Sep 1. PLoS One. 2011. PMID: 21909417 Free PMC article.

7

Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.

Kao SC, Vardy J, Chatfield M, Corte P, Pavlakis N, Clarke C, van Zandwijk N, Clarke S. Kao SC, et al. Clin Lung Cancer. 2013 Jan;14(1):70-7. doi: 10.1016/j.cllc.2012.03.011. Epub 2012 Jun 1. Clin Lung Cancer. 2013. PMID: 22658812

8

Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia.

Kao SC, Clarke S, Vardy J, Corte P, Clarke C, van Zandwijk N. Kao SC, et al. Intern Med J. 2013 Apr;43(4):402-10. doi: 10.1111/j.1445-5994.2012.02925.x. Intern Med J. 2013. PMID: 22909129

9

Health-related quality of life and inflammatory markers in malignant pleural mesothelioma.

Kao SC, Vardy J, Harvie R, Chatfield M, van Zandwijk N, Clarke S, Pavlakis N. Kao SC, et al. Support Care Cancer. 2013 Mar;21(3):697-705. doi: 10.1007/s00520-012-1569-6. Epub 2012 Aug 31. Support Care Cancer. 2013. PMID: 22936495 Clinical Trial.

10

Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma.

Kao SC, Lee K, Klebe S, Henderson D, McCaughan B, Vardy J, Clarke S, van Zandwijk N. Kao SC, et al. Clin Lung Cancer. 2013 Mar;14(2):164-71. doi: 10.1016/j.cllc.2012.09.003. Epub 2012 Oct 17. Clin Lung Cancer. 2013. PMID: 23085037

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

494 results

Search Page

Filters